A detailed history of Raymond James & Associates transactions in Cytosorbents Corp stock. As of the latest transaction made, Raymond James & Associates holds 50,000 shares of CTSO stock, worth $45,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,000
Previous 50,000 -0.0%
Holding current value
$45,000
Previous $35,000 114.29%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 16, 2024

BUY
$1.08 - $1.94 $54,000 - $97,000
50,000 New
50,000 $55,000
Q2 2022

Aug 12, 2022

SELL
$1.76 - $3.22 $152,240 - $278,530
-86,500 Closed
0 $0
Q2 2021

Aug 11, 2021

SELL
$7.55 - $9.42 $993,202 - $1.24 Million
-131,550 Reduced 60.33%
86,500 $653,000
Q1 2021

May 14, 2021

BUY
$8.23 - $11.48 $2,057 - $2,870
250 Added 0.11%
218,050 $1.89 Million
Q4 2020

Feb 12, 2021

SELL
$7.65 - $8.98 $3,825 - $4,490
-500 Reduced 0.23%
217,800 $1.74 Million
Q3 2020

Nov 04, 2020

SELL
$7.37 - $11.54 $11,055 - $17,310
-1,500 Reduced 0.68%
218,300 $1.74 Million
Q1 2020

Apr 21, 2020

BUY
$3.77 - $7.73 $288,405 - $591,345
76,500 Added 53.38%
219,800 $1.7 Million
Q4 2019

Feb 12, 2020

SELL
$3.61 - $5.22 $276,165 - $399,330
-76,500 Reduced 34.8%
143,300 $552,000
Q3 2019

Nov 07, 2019

BUY
$4.33 - $7.63 $220,830 - $389,130
51,000 Added 30.21%
219,800 $1.11 Million
Q4 2018

Feb 11, 2019

BUY
$7.05 - $12.64 $137,475 - $246,480
19,500 Added 13.06%
168,800 $1.36 Million
Q3 2018

Nov 14, 2018

SELL
$10.95 - $14.8 $200,385 - $270,840
-18,300 Reduced 10.92%
149,300 $1.93 Million
Q2 2018

Aug 14, 2018

BUY
$6.9 - $12.35 $3,450 - $6,175
500 Added 0.3%
167,600 $1.91 Million
Q1 2018

May 14, 2018

BUY
$6.55 - $8.2 $439,505 - $550,220
67,100 Added 67.1%
167,100 $1.18 Million
Q4 2017

Feb 14, 2018

BUY
$5.9 - $7.05 $295,000 - $352,500
50,000 Added 100.0%
100,000 $650,000
Q2 2017

Aug 14, 2017

BUY
N/A
50,000
50,000 $215,000

Others Institutions Holding CTSO

About Cytosorbents Corp


  • Ticker CTSO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 43,577,400
  • Market Cap $39.2M
  • Description
  • Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...
More about CTSO
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.